Linvoseltamab

Regeneron's linvoseltamab, when combined with carfilzomib, demonstrated a 90% objective response rate and 76% complete response rate in relapsed/refractory multiple myeloma patients, with 83% remaining progression-free at 12 months.

DARZALEX (daratumumab), Janssen's CD38-targeting monoclonal antibody, has transformed multiple myeloma treatment across all lines of therapy, generating $11.6 billion in worldwide sales in 2024.

Regeneron Pharmaceuticals has reported positive initial results from its Phase 1b LINKER-MM2 trial of linvoseltamab for relapsed/refractory multiple myeloma, demonstrating robust efficacy rates.

Pfizer is prioritizing its oral obesity drug, danuglipron, with late-stage studies planned for the second half of 2025, aiming for a novel mechanism of action.

Bispecific T-cell engagers show promising real-world outcomes for relapsed/refractory large B-cell lymphoma, offering a new treatment avenue.